Introduction
Teicoplanin is a drug with a similar spectrum to vancomycin. Its easy administration and dosage make it advantageous for use in children. Its long half-life permits administration in a single daily dose. 1 The adverse effects of telcoplanin are less frequent than those of vancomycin. 1 The recommendations for teicoplanin dosage have been inferred from studies in healthy adult volunteers. 2 There are few studies that analyse the pharmacokinetics of teicoplanin in children. [3] [4] [5] [6] [7] Critically ill patients present physiopathological alterations (haemodynamic, renal, hepatic, protein concentrations) that can alter antibiotics' distribution, metabolism, elimination and interaction with receptors. Thus, it was necessary to analyse the pharmacokinetics of teicoplanin in critically ill children.
Materials and methods
The study was subject to parental informed consent and ethical approval by the Institutional Review Board. The patients to be included in the study were critically ill children aged between a few days and 15 years, admitted to the paediatric intensive care unit (PICU) requiring treatment with teicoplanin. Three doses of teicoplanin (10 mg/kg by iv bolus) every 12 h followed by one daily dosage of 10 mg/kg were administered. Blood was extracted in order to beasure the levels of teicoplanin at 30 min, 2.6 h and 12 h after the first dose, and before the next dose after 24 h, 48 h, 72 h and on the seventh day of treatment.
Teicoplanin levels were measured by high-performance liquid chromatography (HPLC). Although serum levels of teicoplanin Ͼ5 mg/L can be considered as therapeutic, we accepted values of Ͼ10 mg/L as being desirable levels. [3] [4] [5] [6] The assay specificity was 1 mg/L.
The pharmacokinetic study was performed by compartmental pharmacokinetic analysis. Blood was taken for full blood count, renal function tests (creatinine and urea), hepatic function tests (ALT, AST, gammaglutamyltranspeptidase, alkaline phosphatase, total bilirubin and direct bilirubin), total protein, and albumin before the initiation of treatment and every 48-72 h afterwards, throughout the duration of the study. Adverse reactions that could potentially be attributed to teicoplanin were noted.
Results
Twenty-one children admitted to our PICU with nosocomial infection treated with teicoplanin were included in the study. Fourteen were boys and seven were girls, aged between 7 days and 12 years (seven patients were younger than 3 months, seven patients were between 3 and 12 months and seven patients were older than 12 months). The patients weighed between 2.7 and 40 kg (mean 8.1 ± 9.3 kg).
Eighteen patients were admitted to the PICU in the postoperative period for cardiac surgery, the remaining three for rejection of cardiac transplant, heart failure and encephalitis. Teicoplanin was started because of sepsis in 
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10 patients, pneumonia in eight, surgical wound infection in four and mediastinitis in one (two patients had infections at two sites). No patient presented alteration of hepatic function before treatment. Only one patient had a moderate alteration in renal function (plasma creatinine 1.6 mg/L, clearance of creatinine 55 mL/min per 1.73 m 2 ) which did not require a modification in the therapeutic schedule. The teicoplanin concentrations in this patient were not different from those of the other patients. Teicoplanin was well tolerated, with no adverse effects or alteration in the laboratory parameters attributable to the teicoplanin.
The mean values of serum teicoplanin levels are presented in Table I . Pharmacokinetic analysis demonstrated that the model that best represented the data was the open bicompartmental model. The pharmacokinetic values are shown in Table II . Only 60% of all the teicoplanin concentrations were Ͼ5 mg/L and 25% were Ͼ10 mg/L. Only 11% of trough values were Ͼ10 mg/L. There were no significant differences in the mean serum concentrations and pharmacokinetic characteristics between children Ͼ3 months 3-12 months and Ͼ12 months. The two neonates (7 and 10 days old) did not have different levels from the other patients.
Discussion
We found that teicoplanin has a rapid initial disposition phase, with a mean half-life of 0.79 h, indicating that the initial concentrations of the drug in the central compartment decrease rapidly, mostly due to distribution of the drug to the peripheral compartment and elimination from the central compartment. The values of the distribution volumes CCV and V ss indicate that the drug occupies a large proportion of tissues. Few studies have been carried out on the pharmacokinetics of teicoplanin in paediatric patients [3] [4] [5] and only one in critically ill children. 6 Terragna et al. 4 found in their study that the clearance of teicoplanin in children was similar to that reported for adults, but Dufort et al. 3 and Tarral et al. 5 found increased clear- 
